Unique Features
Implantable Cardiac Devices
AdaptivCRT Algorithm
Clinical Need
Clinical Need
While CRT is a highly effective therapy, there remains a need to improve the percentage of patients who receive full benefits. Studies have shown that up to one-third of patients do not experience all of the benefits of CRT.1-6
Due to the complexity of heart failure disease, many factors contribute to CRT non-response, including suboptimal AV timing, suboptimal LV lead placement, presence of arrhythmias, and reduced BiV pacing.7
As part of its comprehensive approach to treating heart failure patients with CRT, Medtronic offers a variety of solutions across every stage of care, including ways to optimize CRT response.
Up to One-Third of Patients Do Not Experience the
Full Benefit of CRT 1-6
Detail - Adequate CRT Response
Potential Factors Contributing to Suboptimal CRT Response7
Detail - Suboptimal CRT Response
Important Safety Information
For CRT-D devices, certain programming and device operations may not provide cardiac resynchronization therapy. Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features and may impact longevity.
References
1
Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. NEJM. 2002;346(24):1845-1853.
2
Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure; the MIRACLE ICD Trial. JAMA. 2003;289(20):2685-2694.
3
Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110(18):2864-2868.
4
Abraham WT, Leon AR, Hannon C, et al. Results of the InSync III Marquis clinical trial. Heart Rhythm. 2005;2(5): S65.
5
Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation. 2008;117(20):2608-2616.
6
Abraham WT, Gras D, Yu CM, et al. Results from the FREEDOM Trial - assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy. Presented at the Heart Rhythm Society annual scientific session, Denver, CO, May 2010.
7
Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. JACC. 2009; 53(9):765-773.
